

35. Carlsson, SV, Vickers AJ, Lilja H, et al. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? *BJU Int* 2013; 112: 602–609.
36. Catalona, WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol* 2011; 185: 1650.
37. Parekh, DJ, Punnen S, Sjöberg DD, et al. A Multi-institutional prospective trial in the USA confirms that the 4 K score accurately identifies men with high-grade prostate cancer. *Eur Urol* 2015; 68: 464–470.
38. Nordstrom T, Vickers A, Assel M, et al. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. *Eur Urol* 2015; 68: 139.
39. NCCN Clinical Practice Guidelines in Oncology, 2017. Prostate Cancer Early Detection [online]. 2018 [cit.2-4-2021] Dostupné z: www.nccn.org.
40. Nordström T, Vickers A, Assel M, et al. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. *Eur Urol* 2015; 68(1): 139–46.
41. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; 116(2): 281–297.
42. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. miRNAs as biomarkers in prostate cancer. *Clin Transl Oncol* 2012; 14(11): 803–811.
43. Lawrie, CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol* 2008; 141: 672–675.
44. Witwer KW. Circulating microRNA biomarker studies: Pitfalls and potential solutions. *Clin Chem* 2015; 61: 56–63.
45. Lucarelli G, Ditonno P, Bettocchi C, et al. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. *Future Oncol* 2013; 9(6): 899–907.
46. Ferro M, Lucarelli G, Bruzzese D, et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. *Anticancer Res* 2015; 35(2): 1017–1023.
47. Mihelich BL, Maranville JC, Nolley R, et al. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. *PLoS ONE*. 2015; 10: e0124245.
48. Fradet Y, Saad F, Aprikian A, et al. Upm3, a new molecular urine test for the detection of prostate cancer. *Urology* 2004; 64: 311–315.
49. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early – and late-stage human malignancies. *Sci Transl Med* 2014; 6(224): 224ra24.
50. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008; 14: 6302–6309.
51. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, et al. Pten loss in circulating tumour cells correlates with pten loss in fresh tumour tissue from castration-resistant prostate cancer patients. *Br J Cancer*. 2015; 113: 1225–1233.